Unitary Margins at the Crossroads — Data Center MEP Holding Growth
Blue Star's Q2 FY27 preview hinges on margin stabilization after Q1 compression. With copper prices un-passed, watch for evidence of recovery toward the 6.5% target, and confirmation that the ₹3,000 Cr data center MEP pipeline is moving volume.
What to Expect
~₹3,200–3,400 Cr
On-plan 10–15% YoY growth from revised FY27 guide; Q1 was ₹3,377.92 Cr (+13.3% YoY). Q2 seasonally weaker post-monsoon, but data center MEP volumes ramping.
~5.5–6.0%
Q1 compressed to 5.2% from 6.7% due to un-passed copper hikes. Management target for full-year unitary EBIT is 6.5%+. Watch for evidence of price realization and cost normalization in H2.
~₹85–110 Cr
Q1 missed consensus ₹150 Cr at ₹102.5 Cr (-15% YoY). PAT recovery depends on margin stabilization; tax normalization also relevant.
A strong Q2 would show evidence of margin recovery: EBITDA margin trending toward 6.0%+ as copper prices stabilize and price increases gain traction in the market. Revenue growth maintaining the 10–15% YoY guidance range despite seasonal post-monsoon demand dip. Data center MEP segment contributing meaningful revenue (₹350–400 Cr run-rate). PAT above ₹110 Cr. A weak Q2 would see margins stuck below 5.5%, suggesting competitive intensity and raw material pass-through remain blocked. Revenue growth slowing below 10% YoY. Data center MEP unable to offset unitary volume softness.
On Track to Guide?
Management revised FY27 operating margin to 7.5% (from historical 8%+) and guided unitary EBIT margin at 6.5%+ for the full year. Q1 EBITDA margin of 5.2% is materially below that, so H2 (Q3 + Q4) must show step recovery. This is achievable if copper normalizes and price increases are realized, but Q1 miss (PAT ₹102.5 Cr vs ₹150 Cr street consensus) has raised near-term execution risk. Data center MEP is the bright spot: ₹3,000 Cr order inflow guidance for FY27 is tracking, with ₹1,400 Cr revenue expected. If those projects convert and margins hold at 12–14% EBIT, they can offset unitary weakness. Street is watching whether Q2 confirms H2 recovery is credible or whether margin pressure lingers.
What the Street Says
Since Last Quarter
Operations & Strategy: Blue Star divested its MedTech business (Blue Star E&E) to Cyrix Healthcare for up to ₹40 Cr (completed Sep 2, 2026). This is a non-core exit, reducing complexity but immaterial to earnings. The Oman arbitration award (Sep 15, 2026) dismissed claims by W.J. Towell & Co, a favorable legal outcome. Blue Star also approved the strike-off of its step-down subsidiary in U (Oct 14), routine corporate housekeeping.
Ownership & Valuation: FII stake has declined from 16.21% (Q1 FY25) to 12.75% (Q1 FY27), a -3.46 percentage-point slide. This reflects broad EM outflows and stock-specific caution after Q1 margin miss. Promoter stake steady at 36.5%. The stock is at ₹1,564.5, -35.27% from ATH ₹2,417 (likely set during 2024 AI/cooling euphoria), and +9.21% from the 52-week low. RSI 52.1 (neutral) and volume trend normal.
Result Day Watch List
1 · EBITDA Margin & Unitary EBIT
The headline. Management target is 6.5%+ for unitary EBIT in H2. Q1 was 5.2%. If Q2 EBITDA shows step improvement to 5.8–6.2%, bulls can argue H2 recovery is on. Stuck below 5.5% signals risk to full-year guidance and warrant downgrades.
2 · Data Center MEP Revenue & Orders
How much of the ₹3,000 Cr FY27 order guidance is showing up as revenue? Company targeting ₹1,400 Cr for the year; Q2 should show ₹300–400 Cr run-rate if on track. Large orders announced or contract wins signal pipeline credibility.
3 · Price Realization & Competitive Intensity
Management signaled 8 planned price hikes to offset copper. Any color on pass-through success and customer pushback? Competitor moves in unitary segment also matter (Voltas, Daikin). ASP growth or volume decline will hint at pricing power.
4 · Raw Material Cost Trends & FY27 Guide Restatement
Is copper stabilizing? Any update on FX headwinds? Most critical: does management restate FY27 7.5% margin and 6.5% unitary EBIT guidance or cut? A guide cut could trigger 5–10% selloff.
5 · Free Cash Flow & Capex
Data center MEP is project-based and can tie up working capital. Any signal on capex or FCF conversion will matter for cash flow investors and refinancing risk assessment.
Blue Star's Q2 FY27 report (Oct 29) is a margin inflection point. Q1 disappointed on EBITDA and PAT, missing street consensus, and the street is now pricing in material execution risk. The company has ₹3,000 Cr of data center MEP orders flowing through, a structural tailwind, but the unitary core—still 60%+ of EBITDA—is under acute cost pressure. If Q2 shows evidence of copper price stabilization, pricing realization, and H2 margin recovery toward 6.5%+, expect relief and potential 3–5% upside. If margins remain compressed or guidance is trimmed, the stock could face another 5–10% correction toward ₹1,450–1,500.
Watch the EBITDA margin trajectory, data center MEP revenue proof-point, and any management commentary on raw material normalization and H2 visibility.
Blue Star Q2 FY27: PAT +25% YoY but Flat Ex-Exceptional as RAC Margins Stay Squeezed
PAT +25.44% YoY · revenue +21% · margins compressing
₹2,930.95 Cr
+21% YoY
₹123.91 Cr
+25.44% YoY
4.2%
+0.1pp YoY
₹6.03
Blue Star's consolidated PAT rose 25.4% YoY to ₹123.91 Cr on revenue up 21.0% YoY to ₹2,930.95 Cr, but the headline is flattered by a ₹23.02 Cr exceptional gain from the sale of its Medtech business. Strip that out and PBT-before-exceptional items grew just 1.6% YoY (₹134.28 Cr vs ₹132.17 Cr), with adjusted PAT growth around +2% — essentially flat earnings power despite strong topline growth. No formal street consensus specific to this quarter could be located (results were filed same-day); a web search found no Q2 FY27-specific brokerage preview, so vsStreet is unknown rather than assumed.
Q2 FY-2027 vs prior quarters
The margin story is the quarter: consolidated OPM compressed to 6.91% from 7.57% a year ago, and the squeeze is concentrated in the Unitary (room-AC) segment, whose EBIT margin was just 2.31% in Q2 (2.72% for H1) — far below the >6.5% FY27 guidance (aspiring 7-7.5%) management set on last quarter's call. The Electro-mechanical/commercial-AC segment, by contrast, held margin at 6.88% in Q2 (6.83% H1), squarely within its guided 6.5-7% band, so the miss is guidance-specific to RAC, not company-wide. This confirms rather than surprises: management had already been publicly warning that an 8% price hike effective October 1, 2026 would still be insufficient to offset a cumulative ~18% rise in copper, steel and logistics costs since January 2026, with only a fraction of planned hikes passed through due to a delayed summer and competitor pricing pressure.
The stock went into the print at ₹1,673, up 6.2% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
What the summary numbers don't show
₹23.02 Cr exceptional gain from sale of Medtech business by subsidiary Blue Star Engineering & Electronics; H1 exceptional total ₹32.19 Cr also includes a ₹9.17 Cr property-sale gain booked in Q1
FY27 Segment II EBIT margin >6.5% (aspires 7-7.5%); Segment I 6.5-7%. Data center MEP: ₹3,000 Cr order inflow, ₹1,400 Cr revenue FY27; ₹4,000 Crore revenue by FY29. RAC market 18% CAGR potential over 5-year period.
— This quarter: missed
Segment revenue mix shows where growth came from: Unitary products revenue grew 29.4% YoY to ₹897.66 Cr even as its margin collapsed, while Electro-mechanical/commercial-AC grew 16.3% YoY to ₹1,935.99 Cr at a steady margin. The 13.2% QoQ revenue decline (₹3,377.92 Cr to ₹2,930.95 Cr) is pure AC seasonality — Unitary revenue fell 46.9% QoQ as the summer selling season rolled off — not a demand signal. Standalone PAT of ₹38.24 Cr (vs consolidated ₹123.91 Cr) reflects that the Medtech exceptional gain and most overseas-subsidiary contribution sit outside the standalone entity. Separately, Blue Star's Oman arbitration saw WJT's claims dismissed (Sep 15, 2026) — a legal overhang cleared, though not a P&L item this quarter. The filing carries no fresh disclosure on the data-center MEP pipeline (₹3,000 Cr order inflow / ₹1,400 Cr revenue FY27 targets flagged last quarter), so that guidance remains unverified this print.
W1
FY27 Segment II (Unitary/RAC) EBIT margin guided >6.5% (aspiring 7-7.5%) vs just 2.72% in H1 — watch whether the 8% price hike effective Oct 1, 2026 closes the gap in H2
W2
Management flagged input costs (copper, steel, logistics) up ~18% cumulatively since Jan 2026 with price hikes only partially passed through — watch Q3 commentary on whether the latest hike holds against competitor pricing
W3
Data-center MEP pipeline (₹3,000 Cr order inflow, ₹1,400 Cr revenue FY27 target; ₹4,000 Cr revenue by FY29) was not disclosed in this filing — watch for an update next quarter
Consolidated PBT includes a ₹23.02 Cr exceptional gain (Medtech business sale by subsidiary Blue Star Engineering & Electronics); H1 exceptional total ₹32.19 Cr also folds in a ₹9.17 Cr property-sale gain booked in Q1, which sits in the standalone books. NCI of ₹(0.01) Cr makes period profit (123.91) marginally differ from owners'-attributable profit (123.92). All figures legible, limited-review report unmodified.